News & Updates

Show Multimedia Only

Chemo-free regimen a potential new standard of care in paediatric APL

01 Jul 2026 by

In children with newly diagnosed acute promyelocytic leukaemia (APL), the use of a chemotherapy-free treatment protocol is safe and efficacious, according to the early final results of the ICC-APL-02 study.

Chemo-free regimen a potential new standard of care in paediatric APL

01 Jul 2026

Denosumab superior to alendronate for BMD loss prevention in malignant lymphoma

01 Jul 2026 by

The use of denosumab demonstrates superior protection against bone mineral density (BMD) loss at 12 months compared with alendronate in older patients with newly diagnosed lymphoma receiving R-CHOP* and related regimens, as shown in the DENOSULY study.

Denosumab superior to alendronate for BMD loss prevention in malignant lymphoma

01 Jul 2026

[VIDEO]: Metastatic hormone-sensitive prostate cancer case series

01 Jul 2026 by

Prof Axel Merseburger, Chairman of the Department of Urology at the University Hospital of Schleswig-Holstein in Lübeck, Germany, shares four metastatic hormone-sensitive prostate cancer (mHSPC) patient cases, discusses available treatment options and examines how individual characteristics determine optimal management.

[VIDEO]: Metastatic hormone-sensitive prostate cancer case series

01 Jul 2026

Multi-pronged strategy may boost CRC screening uptake in SG

30 Jun 2026 by

A multi-pronged approach can help improve colorectal cancer (CRC) screening uptake in Singapore, suggests a recent study.

Multi-pronged strategy may boost CRC screening uptake in SG

30 Jun 2026

Toripalimab plus gemcitabine-cisplatin shows promise as neoadjuvant treatment in MIBC

29 Jun 2026

Combining toripalimab with gemcitabine and cisplatin chemotherapy is safe and efficacious in patients with muscle-invasive bladder cancer (MIBC), demonstrating its potential as a neoadjuvant treatment (NAT) in a phase II clinical trial.

Toripalimab plus gemcitabine-cisplatin shows promise as neoadjuvant treatment in MIBC

29 Jun 2026

Paradoxical change in microbiome structure tied to gastric cancer, atrophy

28 Jun 2026

A recent study has found a paradoxical change in the microbiome structure in the development of severe gastric mucosal atrophy, which appears to have a significant association with the progression of gastric atrophy and gastric cancer risk.

Paradoxical change in microbiome structure tied to gastric cancer, atrophy

28 Jun 2026

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

24 Jun 2026

Treatment with nivolumab plus relatlimab results in a lower incidence of severe immune-related adverse events (irAEs), delayed onset of irAEs, and reduced rate of treatment discontinuation among patients with advanced cutaneous melanoma when compared with ipilimumab plus nivolumab, reports a study.

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

24 Jun 2026

Hospital pharmacists feel not skilled enough to provide care to cancer patients

24 Jun 2026

Pharmacists working in hospitals do not see themselves competent enough to handle cancer patients, a study has shown.

Hospital pharmacists feel not skilled enough to provide care to cancer patients

24 Jun 2026

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

23 Jun 2026 by

Liposarcoma (LPS) is a rare malignant tumour of adipose tissue, characterized by significant heterogeneity and limited systemic treatment options, particularly in advanced stages. At an industry-sponsored symposium, Dr Herbert Loong of the Chinese University of Hong Kong reviewed advances in systemic therapies for LPS, highlighting clinical evidence supporting the use of eribulin in second-line (2L) and later settings. Dr Olivia Chen, on behalf of the Prince of Wales Hospital sarcoma group, presented a local case of LPS treated with eribulin + lenvatinib, which demonstrated durable clinical benefit over 2 years.

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

23 Jun 2026

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?

23 Jun 2026 by

ARACOG, a phase II randomized trial, reports a significantly greater decline in objectively assessed cognitive function for advanced prostate cancer patients treated with enzalutamide vs darolutamide over 24 weeks, according to data presented at ASCO 2026.

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?

23 Jun 2026

News & Updates

Showing Oncology articles

Showing

Specialty:

Chemo-free regimen a potential new standard of care in paediatric APL

Chemo-free regimen a potential new standard of care in paediatric APL

Denosumab superior to alendronate for BMD loss prevention in malignant lymphoma

Denosumab superior to alendronate for BMD loss prevention in malignant lymphoma

[VIDEO]: Metastatic hormone-sensitive prostate cancer case series

[VIDEO]: Metastatic hormone-sensitive prostate cancer case series

Multi-pronged strategy may boost CRC screening uptake in SG

Multi-pronged strategy may boost CRC screening uptake in SG

Toripalimab plus gemcitabine-cisplatin shows promise as neoadjuvant treatment in MIBC

Toripalimab plus gemcitabine-cisplatin shows promise as neoadjuvant treatment in MIBC

Paradoxical change in microbiome structure tied to gastric cancer, atrophy

Paradoxical change in microbiome structure tied to gastric cancer, atrophy

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

Nivolumab-relatlimab safer than ipilimumab-nivolumab in advanced cutaneous melanoma

Hospital pharmacists feel not skilled enough to provide care to cancer patients

Hospital pharmacists feel not skilled enough to provide care to cancer patients

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

Eribulin in liposarcoma: Clinical benefit and guideline recommendations

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?

ARACOG: Is there a difference in cognitive effects between darolutamide and enzalutamide?